Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,801
  • Shares Outstanding, K 16,081
  • Annual Sales, $ 28,800 K
  • Annual Income, $ 9,390 K
  • 60-Month Beta 0.87
  • Price/Sales 2.05
  • Price/Cash Flow 6.32
  • Price/Book 3.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.50
  • Number of Estimates 3
  • High Estimate -0.42
  • Low Estimate -0.62
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.23 +55.60%
on 03/19/20
4.80 -27.71%
on 03/04/20
-0.91 (-20.78%)
since 03/03/20
3-Month
2.23 +55.60%
on 03/19/20
7.00 -50.43%
on 01/07/20
-2.75 (-44.21%)
since 01/03/20
52-Week
2.23 +55.60%
on 03/19/20
12.30 -71.79%
on 04/08/19
-9.63 (-73.51%)
since 04/03/19

Most Recent Stories

More News
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma

AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company's vascular endothelial growth factor...

AVEO : 3.47 (-5.45%)
AVEO Stops AML Study on Ficlatuzumab Amid Coronavirus Pandemic

AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.

PFE : 33.64 (+2.34%)
LLY : 139.66 (-1.77%)
BMY : 55.53 (+0.58%)
AVEO : 3.47 (-5.45%)
AVEO Oncology and Biodesix to Discontinue CyFi-2 Study of Ficlatuzumab in Relapsed and Refractory AML in Response to Public Health Crisis

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO's potent hepatocyte growth factor...

AVEO : 3.47 (-5.45%)
AVEO Pharmaceuticals (AVEO) Q4 Earnings Beat & Sales Miss

Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.

AZN : 43.96 (+0.46%)
BMY : 55.53 (+0.58%)
BAYRY : 14.3400 (-0.62%)
AVEO : 3.47 (-5.45%)
AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

AVEO : 3.47 (-5.45%)
AVEO: 4Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ AVEO Pharmaceuticals Inc. (AVEO) on Monday reported a fourth-quarter loss of $4.5 million, after reporting a profit in the same period a year earlier.

AVEO : 3.47 (-5.45%)
AVEO Oncology Reports Full Year 2019 Financial Results and Provides Business Update

AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update.

AVEO : 3.47 (-5.45%)
AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO : 3.47 (-5.45%)
CannTrust (CTST) to Report Q4 Earnings: What's in Store?

During CannTrust's (CTST) fourth-quarter earnings call, investor focus will be on the updates pertaining to the company's default status reports and completion of its remediation activities.

AVEO : 3.47 (-5.45%)
CCXI : 38.96 (-1.99%)
CTST : 0.6380 (-9.12%)
HARP : 11.11 (-2.03%)
What's in Store for Axsome (AXSM) This Earnings Season?

On Axsome's (AXSM) fourth-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

AVEO : 3.47 (-5.45%)
CCXI : 38.96 (-1.99%)
AXSM : 55.02 (-1.15%)
HARP : 11.11 (-2.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade AVEO with:

Business Summary

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is...

See More

Key Turning Points

2nd Resistance Point 3.85
1st Resistance Point 3.66
Last Price 3.47
1st Support Level 3.36
2nd Support Level 3.25

See More

52-Week High 12.30
Fibonacci 61.8% 8.45
Fibonacci 50% 7.27
Fibonacci 38.2% 6.08
Last Price 3.47
52-Week Low 2.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar